CD8A and neoplasm: miR-142, by down-regulating PD-L1 expression and blocking the PD-1/PD-L1 pathway, alleviates tumor-induced immune suppression, promoting CD3+ CD8+ T cell proliferation and restoring T cell activity via increased interferon-γ expression.